Jagsonpal Pharmaceuticals Submits Q4FY26 SEBI Compliance Certificate for Dematerialization Process
Jagsonpal Pharmaceuticals Limited filed its Q4FY26 compliance certificate under SEBI Regulation 74(5) for the quarter ended March 31, 2026. The certificate, issued by registrar MCS Share Transfer Agent Limited, confirms proper handling of securities dematerialization process and compliance with regulatory requirements. The company communicated this filing to BSE and NSE, demonstrating its commitment to regulatory adherence.

*this image is generated using AI for illustrative purposes only.
Jagsonpal Pharmaceuticals Limited has submitted its quarterly compliance certificate to stock exchanges, fulfilling regulatory obligations under SEBI (Depositories and Participants) Regulations, 2018. The pharmaceutical company filed the certificate for the quarter ended March 31, 2026, demonstrating its commitment to regulatory compliance.
Regulatory Compliance Details
The certificate was issued under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, which governs the dematerialization process of securities. MCS Share Transfer Agent Limited, serving as the company's registrar and share transfer agent, provided the certification dated April 6, 2026.
| Parameter: | Details |
|---|---|
| Quarter Ended: | March 31, 2026 |
| Certificate Date: | April 6, 2026 |
| Filing Date: | April 10, 2026 |
| Registrar: | MCS Share Transfer Agent Limited |
| Regulation: | SEBI Regulation 74(5) |
Certification Confirmations
The registrar certified compliance with key dematerialization requirements for the quarter. The certificate confirms that within 15 days of receipt of securities for dematerialization:
- Securities comprised in the certificates have been listed on stock exchanges where earlier issued securities are listed
- Certificates have been duly verified, mutilated, and cancelled after proper verification
- The depository name has been substituted in records as the registered owner
Stock Exchange Communication
Jagsonpal Pharmaceuticals communicated the compliance filing to both major Indian stock exchanges. The company is listed on BSE Limited with scrip code 507789 and on National Stock Exchange of India Limited with the symbol JAGSNPHARM.
| Exchange: | Details |
|---|---|
| BSE Scrip Code: | 507789 |
| NSE Symbol: | JAGSNPHARM |
| Company Secretary: | Pratham Rawal |
| CIN: | L74899DL1978PLC009181 |
Corporate Information
The pharmaceutical company operates from its corporate office located at Plot No. 412-415, Nimai Tower, 3rd Floor, Phase-IV, Udyog Vihar, Sector-18, Gurugram, Haryana. Pratham Rawal, serving as Company Secretary and Compliance Officer, signed the regulatory filing on behalf of the company. This quarterly certification represents part of the company's ongoing regulatory compliance framework, ensuring adherence to SEBI guidelines for depositories and participants in the securities market.
Historical Stock Returns for Jagsonpal Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.88% | +4.51% | +10.14% | -11.85% | -7.64% | +526.19% |
What strategic initiatives might Jagsonpal Pharmaceuticals announce in their upcoming annual results for FY2026?
How could potential changes to SEBI's dematerialization regulations impact pharmaceutical companies' compliance costs?
Will Jagsonpal Pharmaceuticals consider expanding its stock exchange listings to international markets given its strong compliance track record?

































